Hengrui Pharmaceutical announced that the subsidiary Beijing Shengdi Pharmaceutical has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-8829 injectable concentrated solution and will carry out clinical trials for the “treatment of acute ischemic stroke with combined edarabone injection”. HRS-8829 is a small molecule drug. Single-drug phase I clinical trials are underway. Combined use with edaravone is expected to provide a new treatment. Up to now, the drug has invested about 16.6 million yuan in research and development. There is uncertainty about drug development and marketing, and the company will proceed with the project and disclose progress in a timely manner.

Hengrui Pharmaceutical announced that the subsidiary Beijing Shengdi Pharmaceutical has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-8829 injectable concentrated solution and will carry out clinical trials for the “treatment of acute ischemic stroke with combined edarabone injection”. HRS-8829 is a small molecule drug. Single-drug phase I clinical trials are underway. Combined use with edaravone is expected to provide a new treatment. Up to now, the drug has invested about 16.6 million yuan in research and development. There is uncertainty about drug development and marketing, and the company will proceed with the project and disclose progress in a timely manner.